Unbiased screening of marine sponge extracts for antiinflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis

ACS Chemical Biology

Volumn 9, Issue 1, 2014, Pages 247-257

  Fung, Shan Yu ^a   Sofiyev, Vladimir ^b   Schneiderman, Julia ^a   Hirschfeld, Aaron F ^a   Victor, Rachel E ^a   Woods, Kate ^b   Piotrowski, Jeff S ^d   Deshpande, Raamesh ^e   Li, Sheena C ^f   De Voogd, Nicole J ^c   Myers, Chad L ^e   Boone, Charlie ^f   Andersen, Raymond J ^b   Turvey, Stuart E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NATURALIS BIODIVERSITY CENTER   (Netherlands)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ELONGATION FACTOR 2; GIROLLINE; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN SYNTHESIS INHIBITOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CHO CELL LINE; COMPARATIVE STUDY; CYTOTOXICITY; DELETION MUTANT; GENE INTERACTION; GENOMICS; HEMATOPOIETIC CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; INNATE IMMUNITY; MACROPHAGE; MARINE SPECIES; MARINE SPONGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STYLISSA CARTERI; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DRUG SCREENING; HUMAN; HUMAN CELL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHO CELLS; CRICETULUS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMIDAZOLES; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MYELOID DIFFERENTIATION FACTOR 88; PORIFERA; PROTEIN BIOSYNTHESIS; TOLL-LIKE RECEPTORS;

EID: 84900445237     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400740     Document Type: Article

References (62)

1. Palm, N. W., and Medzhitov, R. (2009) Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227, 221-233.
2. Takeuchi, O., and Akira, S. (2010) Pattern recognition receptors and inflammation. Cell 140, 805-820.
3. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M., and Hoffmann, J. A. (1996) The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86, 973-983. (Pubitemid 26336801)
4. Moresco, E. M., LaVine, D., and Beutler, B. (2011) Toll-like receptors. Curr. Biol. 21, R488-493.
5. Kawai, T., and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384.
6. Hayashi, F., Smith, K. D., Ozinsky, A., Hawn, T. R., Yi, E. C., Goodlett, D. R., Eng, J. K., Akira, S., Underhill, D. M., and Aderem, A. (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103. (Pubitemid 32391041)
7. Kawai, T., and Akira, S. (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650.
8. Hedayat, M., Netea, M. G., and Rezaei, N. (2011) Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect. Dis. 11, 702-712.
9. Arancibia, S. A., Beltran, C. J., Aguirre, I. M., Silva, P., Peralta, A. L., Malinarich, F., and Hermoso, M. A. (2007) Toll-like receptors are key participants in innate immune responses. Biol. Res. 40, 97-112. (Pubitemid 350111016)
10. Mogensen, T. H. (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240-273.
11. Cinel, I., and Opal, S. M. (2009) Molecular biology of inflammation and sepsis: a primer. Crit. Care Med. 37, 291-304.
12. Kim, H. Y., DeKruyff, R. H., and Umetsu, D. T. (2010) The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat. Immunol. 11, 577-584.
13. Holt, P. G., and Strickland, D. H. (2010) Interactions between innate and adaptive immunity in asthma pathogenesis: new perspectives from studies on acute exacerbations. J. Allergy Clin. Immunol. 125, 963-972 quiz 973-964.
14. Machen, T. E. (2006) Innate immune response in CF airway epithelia: hyperinflammatory? Am. J. Physiol. Cell Physiol. 291, C218-230. (Pubitemid 44148143)
15. Moraes, T. J., Plumb, J., Martin, R., Vachon, E., Cherepanov, V., Koh, A., Loeve, C., Jongstra-Bilen, J., Zurawska, J. H., Kus, J. V., Burrows, L. L., Grinstein, S., and Downey, G. P. (2006) Abnormalities in the pulmonary innate immune system in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 34, 364-374. (Pubitemid 43320718)
16. Bals, R., Weiner, D. J., and Wilson, J. M. (1999) The innate immune system in cystic fibrosis lung disease. J. Clin. Invest. 103, 303-307. (Pubitemid 29069978)
17. Greene, C. M., Branagan, P., and McElvaney, N. G. (2008) Tolllike receptors as therapeutic targets in cystic fibrosis. Expert Opin. Ther. Targets 12, 1481-1495.
18. Doring, G., and Gulbins, E. (2009) Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell. Microbiol. 11, 208-216.
19. Blohmke, C. J., Victor, R. E., Hirschfeld, A. F., Elias, I. M., Hancock, D. G., Lane, C. R., Davidson, A. G., Wilcox, P. G., Smith, K. D., Overhage, J., Hancock, R. E., and Turvey, S. E. (2008) Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J.Immunol. 180, 7764-7773.
20. Turvey, S. E., and Broide, D. H. (2010) Innate immunity. J. Allergy Clin. Immunol. 125, S24-32.
21. Midwood, K. S., Piccinini, A. M., and Sacre, S. (2009) Targeting Toll-like receptors in autoimmunity. Curr. Drug Targets 10, 1139-1155.
22. ONeill, L. A., Bryant, C. E., and Doyle, S. L. (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61, 177-197.
23. Dunne, A., Marshall, N. A., and Mills, K. H. (2011) TLR based therapeutics. Curr. Opin. Pharmacol. 11, 404-411.
24. Barrat, F. J., and Coffman, R. L. (2008) Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol.Rev. 223, 271-283. (Pubitemid 351986175)
25. Tidswell, M., and LaRosa, S. P. (2011) Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Rev. Anti-Infect. Ther. 9, 507-520.
26. Blohmke, C. J., Park, J., Hirschfeld, A. F., Victor, R. E., Schneiderman, J., Stefanowicz, D., Chilvers, M. A., Durie, P. R., Corey, M., Zielenski, J., Dorfman, R., Sandford, A. J., Daley, D., and Turvey, S. E. (2010) TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J.Immunol. 185, 7731-7738.
27. Mohamed, F. B., Garcia-Verdugo, I., Medina, M., Balloy, V., Chignard, M., Ramphal, R., and Touqui, L. (2012) A crucial role of flagellin in the induction of airway mucus production by Pseudomonas aeruginosa. PLoS One 7, e39888.
28. Donia, M., and Hamann, M. T. (2003) Marine natural products and their potential applications as anti-infective agents. Lancet Infect.Dis. 3, 338-348. (Pubitemid 36718012)
29. Brastianos, H. C., Vottero, E., Patrick, B. O., Van, S. R., Matainaho, T., Mauk, A. G., and Andersen, R. J. (2006) Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J. Am. Chem. Soc. 128, 16046-16047. (Pubitemid 44936592)
30. Meimetis, L. G., Williams, D. E., Mawji, N. R., Banuelos, C. A., Lal, A. A., Park, J. J., Tien, A. H., Fernandez, J. G., de Voogd, N. J., Sadar, M. D., and Andersen, R. J. (2012) Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J. Med. Chem. 55, 503-514.
31. Sadar, M. D., Williams, D. E., Mawji, N. R., Patrick, B. O., Wikanta, T., Chasanah, E., Irianto, H. E., Soest, R. V., and Andersen, R. J. (2008) Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org. Lett. 10, 4947-4950.
32. Williams, D. E., Yu, K., Behrisch, H. W., Van, S. R., and Andersen, R. J. (2009) Rolloamides A and B, cytotoxic cyclic heptapeptides isolated from the Caribbean marine sponge Eurypon laughlini. J. Nat. Prod. 72, 1253-1257.
33. Ho, C. H., Piotrowski, J., Dixon, S. J., Baryshnikova, A., Costanzo, M., and Boone, C. (2011) Combining functional genomics and chemical biology to identify targets of bioactive compounds. Curr. Opin. Chem. Biol. 15, 66-78.
34. Parsons, A. B., Brost, R. L., Ding, H., Li, Z., Zhang, C., Sheikh, B., Brown, G. W., Kane, P. M., Hughes, T. R., and Boone, C. (2004) Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22, 62-69. (Pubitemid 38057958)
35. Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L., Toufighi, K., Mostafavi, S., Prinz, J., St Onge, R. P., VanderSluis, B., Makhnevych, T., Vizeacoumar, F. J., Alizadeh, S., Bahr, S., Brost, R. L., Chen, Y., Cokol, M., Deshpande, R., Li, Z., Lin, Z. Y., Liang, W., Marback, M., Paw, J., San Luis, B. J., Shuteriqi, E., Tong, A. H., van Dyk, N., Wallace, I. M., Whitney, J. A., Weirauch, M. T., Zhong, G., Zhu, H., Houry, W. A., Brudno, M., Ragibizadeh, S., Papp, B., Pal, C., Roth, F. P., Giaever, G., Nislow, C., Troyanskaya, O. G., Bussey, H., Bader, G. D., Gingras, A. C., Morris, Q. D., Kim, P. M., Kaiser, C. A., Myers, C. L., Andrews, B. J., and Boone, C. (2010) The genetic landscape of a cell. Science 327, 425-431.
36. Thakur, N. L., and Muller, W. E. G. (2004) Biotechnological potential of marine sponges. Curr. Sci. 86, 1506-1512. (Pubitemid 39234679)
37. Smith, K. D., Andersen-Nissen, E., Hayashi, F., Strobe, K., Bergman, M. A., Barrett, S. L., Cookson, B. T., and Aderem, A. (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4, 1247-1253. (Pubitemid 37540694)
38. Ahond, A., Bedoya-Zurita, M., Colin, M., Fizames, C., Laboute, P., Lavelle, F., Laurent, D., Poupat, C., Pusset, J., Pusset, M., Thoison, O., and Potier, P. (1988) La girolline, nouvelle substance antitumorale extraite de la Ponge, Pseudaxinyssa cantharella n. sp. (Axinellidae). C. R. Acad. Sci. Paris II 307, 145-148.
39. Tsukamoto, S., Yamashita, K., Tane, K., Kizu, R., Ohta, T., Matsunaga, S., Fusetani, N., Kawahara, H., and Yokosawa, H. (2004) Girolline, an antitumor compound isolated from a sponge, induces G2/M cell cycle arrest and accumulation of polyubiquitinated p53. Biol. Pharm. Bull. 27, 699-701. (Pubitemid 41694674)
40. Diop, D., Chauvin, C., Salhi, S., Poupat, C., Ahond, A., and Jean-Jean, O. (2007) Girolline interferes with cell-cycle progression, but not with translation. C. R. Biol. 330, 855-860. (Pubitemid 350187699)
41. Commercon, A., and Paris, J. M. (1991) Enantioselective synthesis of girolline. Tetrahedron Lett. 32, 4905-4906.
42. Oda, K., and Kitano, H. (2006) A comprehensive map of the toll-like receptor signaling network. Mol. Syst. Biol. 2, 2006.
43. Dempsey, P. W., Doyle, S. E., He, J. Q., and Cheng, G. (2003) The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14, 193-209. (Pubitemid 36693141)
44. Parsons, A. B., Lopez, A., Givoni, I. E., Williams, D. E., Gray, C. A., Porter, J., Chua, G., Sopko, R., Brost, R. L., Ho, C. H., Wang, J., Ketela, T., Brenner, C., Brill, J. A., Fernandez, G. E., Lorenz, T. C., Payne, G. S., Ishihara, S., Ohya, Y., Andrews, B., Hughes, T. R., Frey, B. J., Graham, T. R., Andersen, R. J., and Boone, C. (2006) Exploring the mode-of-Action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126, 611-625. (Pubitemid 44163601)
45. Dang, Y., Schneider-Poetsch, T., Eyler, D. E., Jewett, J. C., Bhat, S., Rawal, V. H., Green, R., and Liu, J. O. (2011) Inhibition of eukaryotic translation elongation by the antitumor natural product Mycalamide B. RNA 17, 1578-1588.
46. Dominguez, J. M., Gomez-Lorenzo, M. G., and Martin, J. J. (1999) Sordarin inhibits fungal protein synthesis by blocking translocation differently to fusidic acid. J. Biol. Chem. 274, 22423-22427.
47. Botet, J., Rodriguez-Mateos, M., Ballesta, J. P., Revuelta, J. L., and Remacha, M. (2008) A chemical genomic screen in Saccharomyces cerevisiae reveals a role for diphthamidation of translation elongation factor 2 in inhibition of protein synthesis by sordarin. Antimicrob. Agents Chemother. 52, 1623-1629. (Pubitemid 351614652)
48. Chen, K., Huang, J., Gong, W., Iribarren, P., Dunlop, N. M., and Wang, J. M. (2007) Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 7, 1271-1285. (Pubitemid 47126372)
49. Lavelle, F., Zerial, A., Fizames, C., Rabault, B., and Curaudeau, A. (1991) Antitumor activity and mechanism of action of the marine compound girodazole. Invest. New Drugs 9, 233-244.
50. Catimel, G., Coquard, R., Guastalla, J. P., Merrouche, Y., Le Bail, N., Alakl, M. K., Dumortier, A., Foy, M., and Clavel, M. (1995) Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Cancer Chemother. Pharmacol. 35, 246-248.
51. Colson, G., Rabault, B., Lavelle, F., and Zerial, A. (1992) Mode of action of the antitumor compound girodazole (RP 49532A, NSC 627434). Biochem. Pharmacol. 43, 1717-1723.
52. Pasparakis, M. (2009) Regulation of tissue homeostasis by NFkappaB signalling: implications for inflammatory diseases. Nat. Rev. Immunol. 9, 778-788.
53. Tak, P. P., and Firestein, G. S. (2001) NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107, 7-11. (Pubitemid 32047405)
54. Hoffmann, A., and Baltimore, D. (2006) Circuitry of nuclear factor kappaB signaling. Immunol. Rev. 210, 171-186.
55. Schroeder, S. J., Blaha, G., Tirado-Rives, J., Steitz, T. A., and Moore, P. B. (2007) The structures of antibiotics bound to the E site region of the 50 S ribosomal subunit of Haloarcula marismortui: 13-deoxytedanolide and girodazole. J. Mol. Biol. 367, 1471-1479. (Pubitemid 46413279)
56. Marr, N., and Turvey, S. E. (2012) Role of human TLR4 in respiratory syncytial virus-induced NF-kappaB activation, viral entry and replication. Innate Immun. 18, 856-865.
57. Tang, A., Sharma, A., Jen, R., Hirschfeld, A. F., Chilvers, M. A., Lavoie, P. M., and Turvey, S. E. (2012) Inflammasome-mediated IL-1beta production in humans with cystic fibrosis. PLoS One 7, e37689.
58. Bawa, R., Fung, S. Y., Shiozaki, A., Yang, H., Zheng, G., Keshavjee, S., and Liu, M. (2012) Self-Assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis. Nanomedicine 8, 647-654.
59. Hirschfeld, A. F., Bettinger, J. A., Victor, R. E., Davidson, D. J., Currie, A. J., Ansermino, J. M., Scheifele, D. W., Orange, J. S., and Turvey, S. E. (2007) Prevalence of Toll-like receptor signalling defects in apparently healthy children who developed invasive pneumococcal infection. Clin. Immunol. 122, 271-278. (Pubitemid 46216916)
60. Yan, Z., Costanzo, M., Heisler, L. E., Paw, J., Kaper, F., Andrews, B. J., Boone, C., Giaever, G., and Nislow, C. (2008) Yeast Barcoders: a chemogenomic application of a universal donor-strain collection carrying bar-code identifiers. Nat. Methods 5, 719-725.
61. Smith, A. M., Heisler, L. E., Mellor, J., Kaper, F., Thompson, M. J., Chee, M., Roth, F. P., Giaever, G., and Nislow, C. (2009) Quantitative phenotyping via deep barcode sequencing. Genome Res. 19, 1836-1842.
62. Boyle, E. I., Weng, S., Gollub, J., Jin, H., Botstein, D., Cherry, J. M., and Sherlock, G. (2004) GO::TermFinder-open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 20, 3710-3715. (Pubitemid 40136825)